Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC

This single-arm, multi-center study is to evaluate Sugemalimab plus platinum-based chemotherapy as first-line therapy for patients with locally advanced and metastatic NSCLC in a real-world setting.

Trial Details

NCT ID
NCT07247227
Phase
NA
Sponsor
Peking Union Medical College
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Sugemalimab and Chemotherapy
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Age ≥ 18 years.
  • Patients voluntarily join the study and sign an informed consent form for the study.
  • ECOG PS score 0-3 (patients with PS score 2-3 would be enrolled if due to the tumor disease and anticipated to be improved at investigators' decisi…
  • Histologically documented, stage III, IV non-Small Cell Lung Cancer (according to version 8th of the International Association for the Study of Lun…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →